ArticleThe Journal of antibiotics2023
Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates.
Article in The Journal of antibiotics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- The role of natural products in the intestinal barrier: a bibliometric analysis from 2004 to 2025.Frontiers in immunology · 2026Pooled it
- Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections.Clinical microbiology reviews · 2026Review
- Gut Microbiota and Brain Aging: Identifying Keystone Biomarkers for Cognitive Health.Biomedicines · 2026Review
- Article
- Nutritional strategies to mitigate sub-clinical coccidiosis in Eimeria-challenged broilers.Poultry science · 2026Article
- Re-evaluating gut microbiome signatures of post-antibiotic dietary fiber intake in a large adult cohort.BMC research notes · 2026Article
- Article
- Intestinal mucus acts as a nutrient source and signal forMicrobiome research reports · 2026Article
- Fiber-deprived diet weakens lung defense against antimicrobial-resistantGut microbes reports · 2026Article
- The gut resistome in poultry production: microbial ecology, antibiotic use, and sustainable control approaches.Frontiers in microbiology · 2026Review
- Prospective association between the gut microbiota and incident pneumonia: a cohort study of 6419 individuals.Respiratory research · 2025Article
- The gut microbiome and metabolome in children with a first febrile urinary tract infection: a pilot study.Pediatric nephrology (Berlin, Germany) · 2025Observational
- Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential.Archives of microbiology · 2025Review
- Impact of high frequency electromagnetic radiation on bacterial survival and antibiotic activity in exposed bacteria.Scientific reports · 2025Article
- Complexity of antibiotic resistance and its impact on gut microbiota dynamics.Engineering microbiology · 2025Review
- Isolation of New Strains of Lactic Acid Bacteria from the Vaginal Microbiome of Postmenopausal Women and their Probiotic Characteristics.Current microbiology · 2025Article
- Chinese Sausage Simulates High Calorie-Induced Obesity In Vivo, Identifying the Potential Benefits of Weight Loss and Metabolic Syndrome of Resveratrol Butyrate Monomer Derivatives.Journal of nutrition and metabolism · 2025Article
- The potential of the microbiome as a target for prevention and treatment of carbapenem-resistant Enterobacteriaceae infections.Frontiers in cellular and infection microbiology · 2025Review
- The Impact of Bioactive Molecules from Probiotics on Child Health: A Comprehensive Review.Nutrients · 2024Review
- Exploring Extremotolerant and Extremophilic Microalgae: New Frontiers in Sustainable Biotechnological Applications.Biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a healthy gut microbiota, short chain fatty acids (SCFAs) are produced. The antibacterial action of SCFAs against intestinal pathogens makes them useful for ensuring the safety of food and human health. In this study, we aimed to assess the in vitro inhibitory activity of SCFAs, and to report, for the first time, their impact on the activity of new β-lactam/β-lactamase inhibitor combinations. The minimum inhibitory concentrations of acetic, propionic, and butyric acids were determined against E. coli clinical isolates recovered from gastrointestinal infections. Cefoperazone/sulbactam, ceftazidime/avibactam and cefepime/enmetazobactam are new β-lactam/β-lactamase inhibitor combinations that were studied for their combined therapeutic effects. Also, the effects of pH and concentration of SCFAs were evaluated on in vitro bacterial growth and expression of genes encoding for motility, adhesion, invasion, and biofilm formation. SCFAs were tested at concentrations of 12 mM at pH 7.4 (ileum-conditions), in addition to 60 mM and 123 mM, at pH 6.5 (colon-conditions). The tested SCFAs showed the same MIC (3750 μg ml
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.